サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794669

前立腺がんの治療の世界市場

Prostate Cancer Treatment

出版日
ページ情報
英文 287 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.28円
前立腺がんの治療の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

前立腺がんの治療の世界市場は2030年までに312億米ドルに達する見込み

2024年に214億米ドルと推定される前立腺がんの治療の世界市場は、2024年から2030年にかけてCAGR 6.5％で成長し、2030年には312億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである前立腺手術は、CAGR 8.3％を記録し、分析期間終了時には95億米ドルに達すると予測されます。放射線療法分野の成長率は、分析期間のCAGRで7.3％と推定されます。

米国市場は58億米ドルと推定、中国はCAGR10.5％で成長予測

米国の前立腺がんの治療市場は2024年に58億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに65億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と6.4%と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界の前立腺がんの治療市場- 主要動向と促進要因のまとめ

前立腺がんの治療が個別化治療や標的治療へとシフトしている理由とは？

前立腺がんの治療市場は、個別化医療とプレシジョン・オンコロジーの台頭により大きな変革期を迎えています。前立腺がんは、世界で最も多く診断される悪性腫瘍のひとつであり、従来の手術や放射線治療だけでなく、治療の選択肢が広がっています。免疫療法、アンドロゲン受容体経路阻害剤、放射性リガンド療法、次世代抗アンドロゲン剤における新たなフロンティアは、現在、治療パラダイムを再定義しつつあります。これらの開発は、疾患の進行に影響を与える遺伝子変異、ホルモン反応性、腫瘍微小環境についての理解が深まることによって推進されています。

PARP阻害剤（例えば、オラパリブやルカパリブ）のような標的療法は、BRCA1/2や他の相同組換え修復（HRR）遺伝子変異を有する患者の間で人気を集めています。これらの薬剤は、がん細胞におけるDNA修復を選択的に阻害し、転移性去勢抵抗性前立腺がん（mCRPC）において大きな臨床的利益をもたらします。さらに、次世代シークエンシング（NGS）やリキッドバイオプシー（液体生検）のような精密診断は、腫瘍ゲノミクスのプロファイリングに使用され、腫瘍医が分子シグネチャーに基づいて治療を調整することを可能にしています。このようなゲノム情報に基づいた意思決定へのシフトは、生存率を改善し、低リスク患者の過剰治療を減らすための中心的なものです。

市場情勢を形成しつつある治療モダリティと患者セグメントとは？

歴史的に、前立腺がんの管理は手術（根治的前立腺摘除術）、放射線療法（外照射またはブラキセラピー）、アンドロゲン除去療法（ADT）に依存してきました。これらは依然として基本的な治療法であるが、進行期診断の増加やホルモン抵抗性腫瘍の出現により、より洗練された全身療法への需要が高まっています。高リスクおよび転移性の環境では、ADTとエンザルタミド、アパルタミド、ダロルタミドなどの次世代アンドロゲン受容体阻害薬との併用療法が新たな標準治療となっています。

併存疾患や低悪性度疾患を有する高齢患者は、積極的サーベイランスプログラムからますます恩恵を受けるようになり、侵襲的治療への不必要な曝露を減らしています。逆に、mCRPC患者は現在、前立腺特異的膜抗原（PSMA）陽性細胞に標的放射線を照射するLutetium-177-PSMA-617のような放射性リガンド療法の候補となっています。sipuleucel-T（Provenge）のような免疫治療薬は、がんワクチンの最初の波を代表するものであるが、ロジスティクスの複雑さと控えめな有効性のため、採用はまだ限定的です。患者集団は、リスク層別化、腫瘍生物学、および前治療歴に基づいてより細分化されつつあり、臨床医は多剤併用、病期特異的介入へと向かっています。

技術、医薬品開発、規制の動向は治療アクセスとイノベーションにどのような影響を与えているか？

前立腺がんの治療における技術革新は、強固な医薬品開発パイプラインとそれを支援する規制環境のために加速しています。米国FDAや欧州医薬品庁（EMA）などの機関は、特に遺伝子バイオマーカーを標的とするいくつかの新規治療薬に対して優先審査や画期的治療薬指定を与えています。また、企業はリアルワールドエビデンス（RWE）や適応試験デザインを活用し、承認や市販後調査の迅速化を図っています。コンパニオン診断薬は、最適な患者選択を確実にし、毒性とコストの非効率性を最小化するために、治療薬と共同開発されるようになってきています。

ロボット支援手術（ダ・ヴィンチ・システムなど）、強度変調放射線治療（IMRT）、画像誘導ブラキセラピーなどの進歩は、副作用を最小限に抑えながら治療精度を向上させています。治療計画、病理画像解釈、進行予測にAI対応プラットフォームが導入されつつあります。さらに、フォローアップやPSAモニタリングのための遠隔医療が統合されることで、特に地方や十分なサービスを受けていない地域におけるケアの継続性が向上しています。中低所得国では依然として費用が障壁となっているが、国際的ながんコンソーシアムや世界アクセスプログラムが治療の公平性のギャップを埋めようとしています。

世界の前立腺がんの治療市場の成長を促進する要因は何か？

世界の前立腺がんの治療市場の成長は、男性人口の高齢化、前立腺がん診断の罹患率の上昇、バイオマーカー主導型治療の拡大、高度な介入に対する支払者の支援の増加によってもたらされます。特に先進地域では、一般市民の意識の向上と検診プログラムの拡大が、早期診断と患者の転帰の改善につながっています。同時に、末期がんや進行性前立腺がんの世界の罹患率の上昇により、新規薬剤クラスや精密放射線法の採用が必要となっています。

バイオ医薬品の技術革新も主要な促進要因です。AR-V7スプライスバリアント、PI3K/ACT/mTOR経路、DNA損傷修復機構を標的とする次世代薬剤がいくつか後期臨床開発段階にあります。製薬企業と診断薬企業の提携は、強固な償還の枠組みを持つ標的治療薬の市場参入を加速させています。中国、ブラジル、インドなどの新興市場でも、国のがん対策政策や腫瘍学インフラの拡充を背景に、規制当局による承認や市場参入が加速しています。

同市場の主要企業には、ジョンソン・エンド・ジョンソン（ヤンセン）、ファイザー、アステラス製薬、バイエル、ノバルティス、アストラゼネカ、テリックス・ファーマシューティカルズなどがあります。これらの企業は、臨床試験、分子診断ツール、戦略的買収に投資し、前立腺腫瘍ポートフォリオを強化しています。治療アプローチが慢性疾患管理と個別化治療へとシフトする中、世界市場は外科的治療、薬物治療、放射線治療の各領域で拡大するものと思われます。

セグメント

治療タイプ（前立腺手術、放射線療法、ホルモン療法、化学療法、標的療法、免疫療法）;エンドユーザー（病院エンドユーザー、クリニックエンドユーザー）

調査対象企業の例

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • Exelixis Inc.
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • Fusion Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Myovant Sciences GmbH
  • Novartis AG
  • Pfizer Inc.
  • Point Biopharma
  • Sanofi S.A.
  • Santen Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals（Bausch）

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37838

Global Prostate Cancer Treatment Market to Reach US$31.2 Billion by 2030

The global market for Prostate Cancer Treatment estimated at US$21.4 Billion in the year 2024, is expected to reach US$31.2 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Prostate Surgery, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 10.5% CAGR

The Prostate Cancer Treatment market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Prostate Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Prostate Cancer Treatment Experiencing a Shift Toward Personalized and Targeted Therapies?

The prostate cancer treatment market is undergoing a major transformation with the rise of personalized medicine and precision oncology. Prostate cancer, one of the most commonly diagnosed malignancies among men worldwide, has seen expanded treatment options beyond traditional surgery and radiation. New frontiers in immunotherapy, androgen receptor pathway inhibitors, radioligand therapy, and next-generation anti-androgens are now redefining therapeutic paradigms. These developments are being driven by increasing understanding of genetic mutations, hormone responsiveness, and tumor microenvironments that impact disease progression.

Targeted therapies such as PARP inhibitors (e.g., olaparib and rucaparib) are gaining traction among patients with BRCA1/2 or other homologous recombination repair (HRR) gene mutations. These drugs selectively inhibit DNA repair in cancer cells, offering significant clinical benefits in metastatic castration-resistant prostate cancer (mCRPC). Additionally, precision diagnostics like next-generation sequencing (NGS) and liquid biopsy are being used to profile tumor genomics, enabling oncologists to tailor treatment based on molecular signatures. This shift toward genomic-informed decision-making is central to improving survival rates and reducing overtreatment in low-risk patients.

Which Treatment Modalities and Patient Segments Are Reshaping the Market Landscape?

Historically, prostate cancer management relied on surgery (radical prostatectomy), radiation therapy (external beam or brachytherapy), and androgen deprivation therapy (ADT). While these continue to be foundational interventions, the rise in advanced-stage diagnoses and the emergence of hormone-resistant tumors have intensified demand for more sophisticated systemic therapies. In high-risk and metastatic settings, the combination of ADT with next-generation androgen receptor inhibitors such as enzalutamide, apalutamide, and darolutamide has become the new standard of care.

Older patients with comorbidities or low-grade disease increasingly benefit from active surveillance programs, reducing unnecessary exposure to invasive therapies. Conversely, patients with mCRPC are now candidates for radioligand therapies like Lutetium-177-PSMA-617, which deliver targeted radiation to prostate-specific membrane antigen (PSMA)-positive cells. Immunotherapeutics such as sipuleucel-T (Provenge) represent the first wave of cancer vaccines, although adoption remains limited due to logistical complexity and modest efficacy. The patient population is becoming more segmented based on risk stratification, tumor biology, and prior treatment exposure-guiding clinicians toward multi-modal, stage-specific interventions.

How Are Technology, Drug Development, and Regulatory Dynamics Influencing Treatment Access and Innovation?

Innovation in prostate cancer treatment is accelerating due to a robust drug development pipeline and a supportive regulatory environment. Agencies like the U.S. FDA and European Medicines Agency (EMA) have granted priority review and breakthrough designations for several novel therapies, especially those targeting genetic biomarkers. Companies are also leveraging real-world evidence (RWE) and adaptive trial designs to fast-track approvals and post-marketing surveillance. Companion diagnostics are increasingly co-developed with therapies to ensure optimal patient selection, minimizing toxicity and cost inefficiencies.

Advances in robotic-assisted surgery (e.g., Da Vinci systems), intensity-modulated radiation therapy (IMRT), and image-guided brachytherapy are improving treatment precision while minimizing adverse effects. AI-enabled platforms are now being deployed for treatment planning, pathology image interpretation, and progression prediction. Additionally, the integration of telemedicine for follow-ups and PSA monitoring is enhancing continuity of care, especially in rural or underserved regions. Cost remains a barrier in low- and middle-income countries, though international cancer consortia and global access programs are attempting to bridge the therapeutic equity gap.

What Factors Are Driving the Growth of the Global Prostate Cancer Treatment Market?

The growth in the global prostate cancer treatment market is driven by the aging male population, rising incidence of prostate cancer diagnoses, expanding biomarker-driven therapies, and increased payer support for advanced interventions. Improved public awareness and expanded screening programs, particularly in developed regions, are leading to earlier diagnosis and better patient outcomes. Simultaneously, the rising global prevalence of late-stage or aggressive prostate cancer is necessitating the adoption of novel drug classes and precision radiation methods.

Biopharmaceutical innovation is another key growth driver. Several next-generation agents targeting AR-V7 splice variants, PI3K/AKT/mTOR pathways, and DNA damage repair mechanisms are in late-phase clinical development. Partnerships between pharmaceutical companies and diagnostics firms are accelerating market entry of targeted therapies with robust reimbursement frameworks. Emerging markets such as China, Brazil, and India are also witnessing faster regulatory approvals and market access, backed by national cancer control policies and expanded oncology infrastructure.

Key players in the market include Johnson & Johnson (Janssen), Pfizer Inc., Astellas Pharma, Bayer AG, Novartis AG, AstraZeneca, and Telix Pharmaceuticals. These firms are investing in clinical trials, molecular diagnostic tools, and strategic acquisitions to strengthen their prostate oncology portfolios. As treatment approaches shift toward chronic disease management and individualized care, the global market is set to expand across surgical, pharmaceutical, and radiotherapeutic domains.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy); End-Use (Hospitals End-Use, Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • Exelixis Inc.
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • Fusion Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Myovant Sciences GmbH
  • Novartis AG
  • Pfizer Inc.
  • Point Biopharma
  • Sanofi S.A.
  • Santen Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals (Bausch)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Prostate Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Prostate Cancer Globally Propels Demand for Multi-Modal Therapeutics
    • Innovation in Radiopharmaceuticals Strengthens Business Case for Targeted Therapies
    • Advancements in Genomic and Biomarker Research Expand Personalized Medicine Pathways
    • Rising Use of PSMA-Based Imaging Throws the Spotlight on Precision Diagnosis and Staging
    • Growth in Robotic-Assisted Surgical Procedures Enhances Outcomes in Localized Cancer Treatment
    • Approval of Next-Generation Hormone Therapies Spurs Demand in Castration-Resistant Cases
    • Collaborations With Oncology Networks Support Real-World Data Collection and Insights
    • Development of Novel Androgen Receptor Inhibitors Strengthens Drug Pipeline Depth
    • Expansion of Immunotherapy Applications Encourages Clinical Investigation in Prostate Indications
    • Use of AI in Early Detection Enhances Screening Strategies and Intervention Timing
    • Regulatory Fast-Tracking for Breakthrough Therapies Shortens Time-to-Market for Novel Agents
    • Increasing Adoption of Active Surveillance Approaches Supports Low-Risk Patient Management
    • Surge in Geriatric Population Expands Base of Hormone-Sensitive Patient Groups
    • Entry Into Companion Diagnostics Strengthens Drug-Device Integration Models
    • Growing Use of Proton and Heavy Ion Therapy Accelerates Investment in Radiation Infrastructure
    • Government Funding and Advocacy Efforts Drive Research in Rare and Advanced Prostate Cancers
    • Telehealth Integration for Long-Term Monitoring Improves Continuity of Care Post-Treatment
    • Focus on Reducing Treatment Side Effects Enhances Patient Quality of Life Outcomes
    • Rise in Outpatient-Based Minimally Invasive Procedures Improves Patient Turnaround
    • Cross-Border Clinical Trial Collaborations Enhance Access to Novel Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prostate Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prostate Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Prostate Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Prostate Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Prostate Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Prostate Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Prostate Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Prostate Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Prostate Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Prostate Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Prostate Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Prostate Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Prostate Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Prostate Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Prostate Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Prostate Cancer Treatment by Therapy Type - Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Prostate Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Prostate Cancer Treatment by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Prostate Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION